Company Focus
Roche
Latest Roche News
Biotechnology
Swiss pharma giant Roche has won approval from the UK’s Medicines and Healthcare Regulatory Agency (MHRA) for its combination treatment of Columvi (glofitamab) alongside gemcitabine and oxaliplatin (GemOx) for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant. 17 July 2025
Related News
Insights
Company Spotlight
A clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
Latest News & Features of interest to Roche
Pharmaceutical
French ophthalmology company Nicox has signed an agreement with Japan’s Kowa Company. 17 July 2025
Pharmaceutical
A major collaboration between the Allen Institute and the Aligning Science Across Parkinson’s (ASAP) initiative is set to transform neurodegenerative disease research by integrating Parkinson’s-specific brain cell data into the Allen Brain Cell (ABC) Atlas. The effort is expected to amplify understanding of the cellular mechanisms driving Parkinson’s and other related conditions, offering scientists a high-resolution view into previously inaccessible datasets. 17 July 2025
Biotechnology
French biotech One Biosciences has raised 15 million euros ($16 million) in series A financing to advance development of its clinical-grade single-cell tumor profiling technology. 17 July 2025
Pharmaceutical
Spanish plasma-derived medicines specialist Grifols saw its share close up 7% yesterday, after it revealed that it will invest 160 million euros ($185.6 million) in a new facility in Lliçà de Vall (Barcelona), expanding its industrial footprint in Spain and doubling its plasma fractionation capacity in Europe. 17 July 2025
Biotechnology
US companies SandboxAQ and iOncologi have announced a strategic collaboration to jointly develop, validate, and commercialize a novel high-fidelity mRNA vaccine for glioblastoma, the most common and aggressive malignant brain tumor in adults. 17 July 2025
Biosimilars
South Korea’s Samsung Bioepis today announced it has entered into a license, development and commercialization agreement (DCA) with Harrow, for Samsung Bioepis’ ophthalmology portfolio. 17 July 2025
Biotechnology
Swiss pharma giant Roche has won approval from the UK’s Medicines and Healthcare Regulatory Agency (MHRA) for its combination treatment of Columvi (glofitamab) alongside gemcitabine and oxaliplatin (GemOx) for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant. 17 July 2025
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Kisqali (ribociclib) as an adjuvant treatment for all eligible populations of HR+/HER2- early breast cancer patients. 17 July 2025
Biotechnology
US rare disease meds developer Sarepta Therapeutics late yesterday announced a strategic restructuring plan designed to prioritize high-value, high impact programs, meet its 2027 financial obligations, and support its long-term financial viability. 17 July 2025
Pharmaceutical
Swiss pharma giant Novartis this morning reported second quarter 2025 financial results, showing that net sales were $14.1 billion (+12%, +11% cc), with volume contributing 12 percentage points to growth. This was slightly better than the consensus estimate of $14.02 billion. 17 July 2025
Latest In Brief for Roche
Biotechnology
US biotech Nanoscope Therapeutics has begun a rolling submission to the American medicines regulator for MCO-010, the first gene-agnostic therapy seeking approval for retinitis pigmentosa (RP). 15 July 2025
Latest Related Ones To Watch News
US pharma giant Merck & Co today revealed it has made a bid to acquire UK-based lung therapy company Verona Pharma, sending the latter’s shares up 20.4% to $104.61 in pre-market activity. 13 July 2025
16 June 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze